Table 2.

Impact of Hospital Characteristics on Abandonment of HDC/HCT

		Months to Exit (from January 1, 1999)
Hospital Characteristic	Number of Hospitals	Median	p-Value*
All hospitals	122	15	N/A
Phase III trial site	19	21	.098
Comprehensive cancer center	33	18	.048
Teaching hospital	71	17	.295
HDC/HCT mandate state	29	14	.530
High HDC/HCT 1-year survival rate†	61	15	.833
High HDC/HCT volume (i.e., women with breast cancer)†	61	17	.044
High HCT volume (i.e., breast cancer and other diagnoses)†	61	18	.011
High HDC/HCT volume as a share of total HCT volume†	61	15	.897

^*Statistical significance was assessed using the log-rank test.

^†These outcomes were measured using transplants performed during the period January 1, 1995–December 31, 1997. The sample was split based on the median of each variable. Hospitals in the “High” group have values above the median. The medians are 38% for survival, 42 for HDC/HCT volume, 95 for HCT volume, and 54% for HDC/HCT share.

HCT, hemapoietic cell transplant; HDC, high-dose chemotherapy; N/A, not applicable.